Nanozymes constitute a rapidly advancing frontier in scientific research, attracting widespread international interest, particularly for their role in facilitating cascade reactions. Despite their initial discovery a few years ago, significant hurdles persist in optimizing their catalytic performance and substrate specificity—challenges that are especially critical in the context of biomedical diagnostics. Within this domain, nitrogen-containing graphene oxide-based nanozymes exhibiting peroxidase-mimicking activity have emerged as particularly promising candidates, owing to the exceptional electrical conductivity, mechanical flexibility, and structural resilience of reduced graphene oxide-based materials. Intensive efforts have been devoted to engineering graphene oxide structures to enhance their peroxidase-like functionality. Nonetheless, the practical implementation of such nanozymes remains under active investigation and demands further refinement. This review synthesizes the current developments in nitrogen heteroatom-containing graphene oxide nanozymes and their derivative nanozymes, emphasizing recent breakthroughs and biomedical applications. It concludes by exploring prospective directions and the broader potential of these materials in the biomedical landscape.
Continuous blood pressure (BP) measurement is essential for real-time hypertension management and the prevention of related complications. To address this need, a cuffless BP estimation technique utilizing biosignals from wearable devices has gained significant attention. This study proposes a feasibility approach that integrates microneedle array electrodes (MNE) for ECG acquisition with photoplethysmogram (PPG) sensors for cuffless BP estimation. The algorithm employed is a baseline multivariate regression model using PTT and RR intervals, while the novelty lies in the hardware design aimed at improving signal quality and long-term wearability. The algorithm’s performance was validated using the Medical Information Mart for Intensive Care (MIMIC) database, achieving a mean error range of ±5.28 mmHg for the SBP and ±2.81 mmHg for the DBP. Additionally, the comparison with 253 measurements from three volunteers against an automated sphygmomanometer indicated an accuracy within ±25%. Therefore, these findings demonstrate the feasibility of an MNE-based ECG with PPG for BP integration for cuffless monitoring of SBP and DBP in daily life. The MIMIC-based evaluation was performed to verify the feasibility of the regression model under ideal public-database conditions. The volunteer experiment, performed with the developed MNE-ECG hardware, served as a separate preliminary feasibility test to observe hardware behavior in real-world measurements.